We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients (APIs) and formulations, and life cycle management (LCM) products such as Depot long acting injections. The company’s lead product is Glatiramer Acetate (GA, Copaxone®) Depot, a once-monthly IM injection of 40mg GA for the treatment of multiple sclerosis (a $20 billion market). Mapi is engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, as well as Risperidone LAI, Paliperidone Palmitate and Buspirone ER for the treatment of schizophrenia. The company is also developing a portfolio of 20 products. Mapi Pharma Ltd. was founded in 2008 and is located in Ness Ziona, Israel and has GMP approved API and FDF facilities.